Market Environment

Canada plays a significant role in the US$20 billions contractual research market. It offers excellent academics and top class researchers with good patient populations, excellent cost structures and leading R&D fiscal incentives.

It is estimated that Canada offers a 16% cost advantage over the USA in quality clinical trials management costs (1).

Furthermore, recent changes in the country’s legislation allow for faster study starts thanks to a maximum delay of 30 days in file submissions for phase I studies and 7 days for bioequivalence studies.

Submission requirements are well harmonized with the U.S. FDA.

The province of Quebec is a stronghold for Canadian contractual research. The pharmaceutical industry spends annually over US$100 millions in clinical trials in the Province. Montreal is the active heart of this vital industry employing more than 4,000 people in the metropolitan area. It ranks first in Canada for CROs.

The Montreal region benefits from a very receptive population that is generally sympathetic to clinical studies. Its long and successful history of clinical studies as well as its 4 universities and a favourable employment structure make it easier for sponsors and CROs to recruit study participants.

(1) Source: Industry Canada, Life Sciences Branch.

This document had been prepared by: Montréal International

This document had been prepared by: Montréal International